Table 3 Association between study treatment and adverse events (of moderate or greater severity) within the first 14 days of treatment, stratified by age group
Adverse events | Comparison groups | Age < 5 years | Age ≥ 5 years | ||
|---|---|---|---|---|---|
| Â | Â | RR (95% CI) | p-value | RR (95% CI) | p-value |
Anorexia | AQ+SP vs. AL | 3.82 (1.59–9.17) | 0.003 | 1.73 (0.79–3.81) | 0.17 |
|  | AQ+SP vs. AS+AQ | 2.10 (1.04–4.23) | 0.04 | 1.32 (0.64–2.71) | 0.46 |
Weakness | AQ+SP vs. AL | 5.40 (1.86–15.7) | 0.002 | 3.08 (1.17–8.14) | 0.02 |
|  | AQ+SP vs. AS+AQ | 2.26 (1.01–5.05) | 0.04 | 1.68 (0.76–3.69) | 0.20 |
Subjective fever | AQ+SP vs. AL | 1.55 (0.78–3.10) | 0.21 | 1.78 (1.08–2.93) | 0.02 |
|  | AQ+SP vs. AS+AQ | 1.22 (0.64–2.31) | 0.54 | 2.80 (1.53–5.12) | 0.001 |
Elevated temperature | AL vs. AQ+SP or AS+AQ | 1.34 (0.60–3.03) | 0.47 | 3.66 (1.59–8.41) | 0.002 |